Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients

Otology and Neurotology

Volumn 35, Issue 1, 2014, Pages

  Plotkin, Scott R ^a   Merker, Vanessa L ^a   Muzikansky, Alona ^a   Barker II, Fred G ^a   Slattery, William ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Neurotology House Clinic   (United States)

Author keywords

Natural history; Neurofibromatosis 2; Vestibular schwannoma; Word recognition score

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE COURSE; FEMALE; HEARING IMPAIRMENT; HUMAN; MALE; MIDDLE AGED; NEUROFIBROMATOSIS; NEUROMA; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84891789597     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0000000000000239     Document Type: Article

References (28)

1. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009;373:1974-86
2. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007;60:460-8
3. Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997;40:696-705
4. Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012; 14:1163-70
5. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010;31:1135-43
6. Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients. Otol Neurotol 2012;33: 1046-52
7. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 2002;96:217-22
8. Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 2012;117:109-17
9. Ito E, Saito K, Yatsuya H, et al. Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev 2009;32:425-33
10. Mautner VF, Baser ME, Thakkar SD, et al. Vestibular schwannoma growth in patients with neurofibromatosis type 2: A longitudinal study. J Neurosurg 2002;96:223-8
11. Peyre M, Goutagny S, Bah A, et al. Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: Hearing and tumor growth results. Neurosurgery 2013; 72:907-13
12. Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 2012;158A: 24-41
13. Plotkin SR, Halpin C, Blakeley JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009;93: 61-77
14. Fisher LM, Doherty JK, Lev MH, et al. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2. Otol Neurotol 2007;28:1083-90
15. Fisher LM, Doherty JK, Lev MH, et al. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: Neurofibromatosis 2 natural history consortium. Otol Neurotol 2009;30:835-41
16. Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 2004; 25:150-4
17. Slattery WH III, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 2004;25:811-7
18. Slattery WH, Lev MH, Fisher LM, et al. MRI evaluation of neurofibromatosis 2 patients: A standardized approach for accuracy in interpretation. Otol Neurotol 2005;26:733-40
19. NIH Consensus Conference. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988;45:575-8
20. Monsell EM. New and revised reporting guidelines from the Committee on Hearing and Equilibrium. American Academy of OtolaryngologyYHead and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:176-8
21. Hirsch IJ, Davis H, Silverman SR, et al. Development of materials for speech audiometry. J Speech Hear Disord 1952;17:321-37
22. Halpin C, Rauch SD. Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol 2006;27:110-6
23. Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21:507-18
24. Gurgel RK, Jackler RK, Dobie RA, et al. A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg 2012;147:803-807
25. Huang X, Caye-Thomasen P, Stangerup SE. Distinct spontaneous shrinkage of a sporadic vestibular schwannoma. Auris Nasus Larynx 2013;40:243-6
26. Harris GJ, Plotkin SR, MacCollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008;62:1314-9
27. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet A 2010;152A:327-32
28. Asthagiri AR, Vasquez RA, Butman JA, et al. Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One 2012;7:e46132